Literature DB >> 23097390

A critical overview on ticagrelor in acute coronary syndromes.

E P Navarese1, A Buffon, M Kozinski, K Obonska, M Rychter, V Kunadian, D Austin, S De Servi, A Sukiennik, J Kubica.   

Abstract

Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23097390     DOI： 10.1093/qjmed/hcs187

Source DB:  PubMed          Journal:  QJM        ISSN： 1460-2393


  8 in total

1.  Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest.

Authors:  Julia M Umińska; Jakub Ratajczak; Katarzyna Buszko; Przemysław Sobczak; Wiktor Sroka; Michał P Marszałł; Piotr Adamski; Klemen Steblovnik; Marko Noč; Jacek Kubica
Journal:  Cardiol J       Date:  2019-02-25       Impact factor: 2.737

2.  Ticagrelor alleviates high-carbohydrate intake induced altered electrical activity of ventricular cardiomyocytes by regulating sarcoplasmic reticulum-mitochondria miscommunication.

Authors:  Yusuf Olgar; Aysegul Durak; Sinan Degirmenci; Erkan Tuncay; Deniz Billur; Semir Ozdemir; Belma Turan
Journal:  Mol Cell Biochem       Date:  2021-06-10       Impact factor: 3.396

3.  Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial.

Authors:  Jacek Kubica; Piotr Adamski; Małgorzata Ostrowska; Marek Koziński; Karolina Obońska; Ewa Laskowska; Ewa Obońska; Grzegorz Grześk; Piotr Winiarski; Przemysław Paciorek
Journal:  Trials       Date:  2015-04-29       Impact factor: 2.279

4.  Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study.

Authors:  Piotr Adamski; Małgorzata Ostrowska; Joanna Sikora; Karolina Obońska; Katarzyna Buszko; Magdalena Krintus; Grażyna Sypniewska; Michał Piotr Marszałł; Marek Koziński; Jacek Kubica
Journal:  BMJ Open       Date:  2017-04-26       Impact factor: 2.692

5.  Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2Y12 inhibitors.

Authors:  Benjamin Panzer; Patricia P Wadowski; Kurt Huber; Simon Panzer; Thomas Gremmel
Journal:  Diabet Med       Date:  2022-05-16       Impact factor: 4.213

6.  Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials.

Authors:  Eliano P Navarese; Safi U Khan; Michalina Kołodziejczak; Jacek Kubica; Sergio Buccheri; Christopher P Cannon; Paul A Gurbel; Stefano De Servi; Andrzej Budaj; Antonio Bartorelli; Daniela Trabattoni; E Magnus Ohman; Lars Wallentin; Matthew T Roe; Stefan James
Journal:  Circulation       Date:  2020-05-29       Impact factor: 29.690

7.  High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells.

Authors:  Grzegorz Grześk; Marek Kozinski; Udaya S Tantry; Michal Wicinski; Tomasz Fabiszak; Eliano P Navarese; Elzbieta Grzesk; Young-Hoon Jeong; Paul A Gurbel; Jacek Kubica
Journal:  Biomed Res Int       Date:  2013-06-06       Impact factor: 3.411

Review 8.  Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls.

Authors:  Max-Paul Winter; Marek Koziński; Jacek Kubica; Daniel Aradi; Jolanta M Siller-Matula
Journal:  Postepy Kardiol Interwencyjnej       Date:  2015-01-12       Impact factor: 1.426
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.